Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcus Biosciences, Inc.RCUS · Entity 4104 | Director · Chief Executive Officer | January 23, 2026 | January 27, 2026 |
| IDEAYA Biosciences, Inc.IDYA · Entity 4069 | Director | June 16, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcus Biosciences, Inc.
Report date January 23, 2026 · Filed January 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,236,409 |
Reported balance
After 2026-01-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-23 · Grant · Acquired 79,000 · Balance 2,236,409 F1: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company. F2: Includes the unvested portion of the Reporting Person's RSU grants. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.13 · Expires 2036-01-22 | Direct | 315,000 |
Reported balance
After 2026-01-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-23 · Grant · Acquired 315,000 · Balance 315,000 F3: The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company.
F2: Includes the unvested portion of the Reporting Person's RSU grants.
F3: The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.
IDEAYA Biosciences, Inc.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.57 · Expires 2036-06-16 | Direct | 20,000 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 20,000 · Balance 20,000 F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 18, 2026 20:33 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $30.57 | $0.00 |
DisclosureSEC source: 0001610717-26-000263 · form4.xml · derivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2036-06-16 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 01:21 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 315,000 | $0.00 Strike: $22.13 | $0.00 |
DisclosureSEC source: 0001182473-26-000005 · wk-form4_1769476905.xml · derivative · entry 2 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 315,000 Underlying: Common Stock · 315,000 shares Expires 2036-01-22 F3 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 01:21 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 79,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001182473-26-000005 · wk-form4_1769476905.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,236,409 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company. F2 · balance_after: Includes the unvested portion of the Reporting Person's RSU grants. Read SEC document |
| January 08, 2026 Filed Jan 9, 2026 21:26 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GiftCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001182473-26-000003 · wk-form4_1767993968.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,157,409 F1 · kind: Represents a charitable gift by the reporting person. F2 · balance_after: Includes the unvested portion of the reporting person's RSU grants. Read SEC document |
| December 30, 2025 Filed Jan 2, 2026 21:18 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GiftCommon Stock | 2,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000001 · form4.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,192,409 F1 · kind: 2,400 shares were transferred to various family trusts in which the reporting person has no pecuniary interest, but retains voting and dispositive power over all of the shares transferred to each trust. Read SEC document |
| December 17, 2025 Filed Dec 18, 2025 22:35 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 25,744 | $22.16 | $570,474.17 |
DisclosureSEC source: 0001182473-25-000005 · wk-form4_1766097299.xml · nonDerivative · entry 2 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,194,809 F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person. F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.92 to $22.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 236 shares purchased on November 30, 2025 through the Company's Employee Stock Purchase Plan. F4 · balance_after: Includes the unvested portion of the reporting person's RSU grants. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 22:35 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 28,947 | $21.88 | $633,484.83 |
DisclosureSEC source: 0001182473-25-000005 · wk-form4_1766097299.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,220,553 F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.42 to $22.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 236 shares purchased on November 30, 2025 through the Company's Employee Stock Purchase Plan. F4 · balance_after: Includes the unvested portion of the reporting person's RSU grants. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 20:54 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $21.78 | $0.00 |
DisclosureSEC source: 0001610717-25-000260 · form4.xml · derivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-06-24 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 00:05 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 19,800 | $10.18 | $201,465.00 |
DisclosureSEC source: 0001724521-25-000045 · wk-form4_1740701149.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,554,160 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.13 to $10.185, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:30 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 650,000 | $0.00 Strike: $13.33 | $0.00 |
DisclosureSEC source: 0001724521-25-000020 · wk-form4_1738013445.xml · derivative · entry 2 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2035-01-22 F2 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2025, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:30 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 165,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001724521-25-000020 · wk-form4_1738013445.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,534,360 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2025, subject to the Reporting Person's continued service to the Company. Read SEC document |
| December 15, 2024 Filed Dec 18, 2024 01:36 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Tax withholdingCommon Stock | 37,882 | $16.08 | $609,142.56 |
DisclosureSEC source: 0001724521-24-000182 · wk-form4_1734485794.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,369,360 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy the applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. F2 · balance_after: This amount reflects 1,547,062 shares of the Issuer's Common Stock that are no longer beneficial owned by the Reporting Person as a result of him entering into a "domestic relations order", which change in beneficial ownership is exempt from Section 16 pursuant to Rule 16a-12 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 15, 2024 Filed Jun 18, 2024 20:54 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Tax withholdingCommon Stock | 12,670 | $16.97 | $215,009.90 |
DisclosureSEC source: 0001724521-24-000129 · wk-form4_1718744059.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,954,304 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy the applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| May 31, 2024 Filed May 31, 2024 20:38 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 16,200 | $0.00 Strike: $36.55 | $0.00 |
DisclosureSEC source: 0001610717-24-000279 · form4.xml · derivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,200 Underlying: Common Stock · 16,200 shares Expires 2034-05-30 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 00:39 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 405,900 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001724521-24-000026 · wk-form4_1706229555.xml · derivative · entry 2 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 405,900 Underlying: Common Stock · 405,900 shares Expires 2034-01-22 F2 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2024, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 00:39 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001724521-24-000026 · wk-form4_1706229555.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,966,974 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2024, subject to the Reporting Person's continued service to the Company. Read SEC document |
| December 29, 2023 Filed Jan 2, 2024 22:44 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | OtherCommon Stock | 448 | $0.00 | $0.00 |
DisclosureSEC source: 0001724521-24-000003 · wk-form4_1704235482.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,866,974 Read SEC document |
| December 19, 2023 Filed Dec 20, 2023 21:09 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Disposition to issuerCommon Stock | 14,000 | $18.09 | $253,260.00 |
DisclosureSEC source: 0001724521-23-000064 · wk-form4_1703106555.xml · nonDerivative · entry 2 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,866,526 F1 · shares: Represents shares sold by the Issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.78 to $18.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 21:09 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Disposition to issuerCommon Stock | 13,705 | $17.74 | $243,126.70 |
DisclosureSEC source: 0001724521-23-000064 · wk-form4_1703106555.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,880,526 F1 · shares: Represents shares sold by the Issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.45 to $17.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 16, 2023 Filed Jun 17, 2023 00:12 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Disposition to issuerCommon Stock | 8,762 | $19.35 | $169,544.70 |
DisclosureSEC source: 0001209191-23-038152 · doc4.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,894,231 F1 · shares: Represents shares sold by the Issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.86 to $19.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 3,433,870 shares that were previously indirectly held by the reporting person through The Rosen Family Trust. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:44 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 16,200 | $0.00 Strike: $25.40 | $0.00 |
DisclosureSEC source: 0001610717-23-000111 · form4.xml · derivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,200 Underlying: Common Stock · 16,200 shares Expires 2033-06-06 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 22:49 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 429,000 | $0.00 Strike: $22.02 | $0.00 |
DisclosureSEC source: 0001209191-23-004870 · doc4.xml · derivative · entry 3 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,000 Underlying: Common Stock · 429,000 shares Expires 2033-01-22 F2 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2023, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 22:49 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 105,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004870 · doc4.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469,123 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Company. Read SEC document |
| December 16, 2022 Filed Dec 17, 2022 02:39 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 2,060 | $31.23 | $64,333.80 |
DisclosureSEC source: 0001209191-22-061758 · doc4.xml · nonDerivative · entry 2 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,173 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.05 to $31.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 16, 2022 Filed Dec 17, 2022 02:39 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 10,983 | $30.66 | $336,738.78 |
DisclosureSEC source: 0001209191-22-061758 · doc4.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,233 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.05 to $31.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 20:21 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 3,252 | $22.29 | $72,487.08 |
DisclosureSEC source: 0001209191-22-038396 · doc4.xml · nonDerivative · entry 3 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,716 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.14 to $22.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 20:21 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 1,361 | $21.71 | $29,547.31 |
DisclosureSEC source: 0001209191-22-038396 · doc4.xml · nonDerivative · entry 2 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,968 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.14 to $22.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 20:21 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 4,241 | $20.72 | $87,873.52 |
DisclosureSEC source: 0001209191-22-038396 · doc4.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,329 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.33 to $21.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 22:32 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $12.29 | $0.00 |
DisclosureSEC source: 0001567619-22-012700 · doc1.xml · derivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 22:04 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 275,000 | $0.00 Strike: $33.03 | $0.00 |
DisclosureSEC source: 0001209191-22-017967 · doc4.xml · derivative · entry 4 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2032-03-07 F4 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 1, 2022, subject to the Reporting Person's continued service to the Company. Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 22:04 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017967 · doc4.xml · nonDerivative · entry 2 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,570 F2 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2022, subject to the Reporting Person's continued service to the Company. Read SEC document |
| March 07, 2022 Filed Mar 10, 2022 22:04 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GiftCommon Stock | 321,074 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017967 · doc4.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Rosen GRAT No. 2 Disclosed balance after: 0 F1 · balance_after: 321,074 shares were transferred to various family trusts in which the reporting person has no pecuniary interest, but retains voting and dispositive power over all of the shares transferred to each trust. The remaining 62,930 shares were transferred into the Rosen Family Trust in a transaction exempt from Section 16 reporting pursuant to Rule 16a13. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 21:16 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 1,065 | $41.42 | $44,116.35 |
DisclosureSEC source: 0001209191-21-070557 · doc4.xml · nonDerivative · entry 6 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,570 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F7 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.10 to $41.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 21:16 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 808 | $40.57 | $32,783.15 |
DisclosureSEC source: 0001209191-21-070557 · doc4.xml · nonDerivative · entry 5 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,635 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F6 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.10 to $41.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 21:16 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 417 | $39.67 | $16,543.18 |
DisclosureSEC source: 0001209191-21-070557 · doc4.xml · nonDerivative · entry 4 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,443 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.10 to $40.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 21:16 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 653 | $38.79 | $25,328.37 |
DisclosureSEC source: 0001209191-21-070557 · doc4.xml · nonDerivative · entry 3 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,860 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.10 to $39.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 21:16 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 619 | $40.46 | $25,042.57 |
DisclosureSEC source: 0001209191-21-070557 · doc4.xml · nonDerivative · entry 2 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,513 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.12 to $40.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 21:16 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 1,680 | $39.59 | $66,513.89 |
DisclosureSEC source: 0001209191-21-070557 · doc4.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,132 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.11 to $40.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:53 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 4,863 | $23.68 | $115,155.84 |
DisclosureSEC source: 0001209191-21-042080 · doc4.xml · nonDerivative · entry 3 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,562 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.395 to $24.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:53 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 159 | $24.77 | $3,938.43 |
DisclosureSEC source: 0001209191-21-042080 · doc4.xml · nonDerivative · entry 2 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,425 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.63 to $24.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:53 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 3,809 | $24.13 | $91,911.17 |
DisclosureSEC source: 0001209191-21-042080 · doc4.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,584 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.61 to $24.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 10, 2021 Filed Jun 16, 2021 21:04 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $21.66 | $0.00 |
DisclosureSEC source: 0001567619-21-012206 · doc1.xml · derivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 22:02 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GiftCommon Stock | 311,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-007780 · doc4.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Rosen GRAT No. 1 Disclosed balance after: 0 F1 · balance_after: 311,900 shares were transferred to various family trusts in which the reporting person has no pecuniary interest, but retains voting and dispositive power over all of the shares transferred to each trust. The remaining 86,450 shares were transferred into the Rosen Family Trust in a transaction exempt from Section 16 reporting pursuant to Rule 16a13. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:14 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 280,000 | $0.00 Strike: $36.73 | $0.00 |
DisclosureSEC source: 0001209191-21-004277 · doc4.xml · derivative · entry 5 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2031-01-18 F2 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 1, 2021, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:14 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004277 · doc4.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,393 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments after January 1, 2021, subject to the Reporting Person's continued service to the Company. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 21:13 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 32,050 | $23.38 | $749,402.72 |
DisclosureSEC source: 0001209191-20-046182 · doc4.xml · nonDerivative · entry 2 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Rosen Family Trust Disclosed balance after: 3,231,179 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.69 to $23.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F2 · balance_after: 101,650 and 62,685 shares previously held by the reporting person in Rosen GRAT No. 1 and No. 2, respectively, were transferred into the Rosen Family Trust in a transaction exempt from Section 16 reporting pursuant to Rule 16a13. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 21:13 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 11,655 | $21.44 | $249,911.17 |
DisclosureSEC source: 0001209191-20-046182 · doc4.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Rosen Family Trust Disclosed balance after: 3,199,129 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.11 to $21.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F2 · balance_after: 101,650 and 62,685 shares previously held by the reporting person in Rosen GRAT No. 1 and No. 2, respectively, were transferred into the Rosen Family Trust in a transaction exempt from Section 16 reporting pursuant to Rule 16a13. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 20:43 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $12.84 | $0.00 |
DisclosureSEC source: 0001567619-20-012376 · doc1.xml · derivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2030-06-15 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:35 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034995 · doc4.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,393 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments after June 4, 2020, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 15:57 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 350,000 | $0.00 Strike: $10.23 | $0.00 |
DisclosureSEC source: 0001209191-20-004405 · doc4.xml · derivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2029-12-31 F1 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 1, 2020, subject to the Reporting Person's continued service to the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.